Related Experiment Video
Updated: Feb 23, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Neuropathology of White Matter Lesions, Blood-Brain Barrier Dysfunction, and Dementia
Atticus H Hainsworth1, Thais Minett2, Joycelyn Andoh2
1From the Cell Biology and Genetics Research Centre (A.H.H., J.A., I.B., L.R.B.) and Neuroscience Research Centre (A.H.H., J.A., I.B., T.R.B., L.R.B.), Molecular and Clinical Sciences Research Institute, St George's University of London, United Kingdom; Department of Neurology (A.H.H.) and Department of Cellular Pathology (K.E., J.J., L.R.B.), St George's University Hospitals NHS Foundation Trust, London, United Kingdom; Department of Public Health and Primary Care (T.M.), Department of Radiology (T.M.), and Stroke Research Group, Department of Clinical Neurosciences (H.S.M.), University of Cambridge, United Kingdom; and The Sheffield Institute for Translational Neuroscience, University of Sheffield, United Kingdom (G.F.). ahainsworth@sgul.ac.uk.
Background And Purpose:
We tested whether blood-brain barrier dysfunction in subcortical white matter is associated with white matter abnormalities or risk of clinical dementia in older people (n=126; mean age 86.4, SD: 7.7 years) in the MRC CFAS (Medical Research Council Cognitive Function and Ageing Study).
Methods:
Using digital pathology, we quantified blood-brain barrier dysfunction (defined by immunohistochemical labeling for the plasma marker fibrinogen). This was assessed within subcortical white matter tissue samples harvested from postmortem T2 magnetic resonance imaging (MRI)-detected white matter hyperintensities, from normal-appearing white matter (distant from coexistent MRI-defined hyperintensities), and from equivalent areas in MRI normal brains. Histopathologic lesions were defined using a marker for phagocytic microglia (CD68, clone PGM1).
Results:
Extent of fibrinogen labeling was not significantly associated with white matter abnormalities defined either by MRI (odds ratio, 0.90; 95% confidence interval, 0.79-1.03; P=0.130) or by histopathology (odds ratio, 0.93; 95% confidence interval, 0.77-1.12; P=0.452). Among participants with normal MRI (no detectable white matter hyperintensities), increased fibrinogen was significantly related to decreased risk of clinical dementia (odds ratio, 0.74; 95% confidence interval, 0.58-0.94; P=0.013). Among participants with histological lesions, increased fibrinogen was related to increased risk of dementia (odds ratio, 2.26; 95% confidence interval, 1.25-4.08; P=0.007).
Conclusions:
Our data suggest that some degree of blood-brain barrier dysfunction is common in older people and that this may be related to clinical dementia risk, additional to standard MRI biomarkers.
More Related Videos
06:19Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
Published on: October 20, 2023
07:22Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
Published on: November 8, 2017
Related Concept Videos
The Blood-brain Barrier
Dementia
The progression of dementia is generally gradual....
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...